Jelena Klawitter
Concepts (526)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Kidney, Autosomal Dominant | 14 | 2024 | 262 | 4.280 |
Why?
| | Kidney | 20 | 2024 | 1468 | 2.600 |
Why?
| | Tandem Mass Spectrometry | 15 | 2024 | 532 | 2.500 |
Why?
| | Metabolomics | 20 | 2022 | 678 | 2.460 |
Why?
| | Cardiopulmonary Bypass | 10 | 2025 | 209 | 2.250 |
Why?
| | Immunosuppressive Agents | 15 | 2019 | 890 | 1.850 |
Why?
| | Chromatography, High Pressure Liquid | 14 | 2024 | 597 | 1.820 |
Why?
| | Oxidative Stress | 18 | 2020 | 1317 | 1.710 |
Why?
| | Cyclosporine | 10 | 2019 | 268 | 1.670 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2017 | 437 | 1.240 |
Why?
| | Metabolome | 8 | 2022 | 350 | 1.190 |
Why?
| | Sirolimus | 9 | 2019 | 276 | 1.140 |
Why?
| | Cardiac Surgical Procedures | 3 | 2022 | 530 | 1.090 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 1.070 |
Why?
| | Energy Metabolism | 8 | 2022 | 922 | 0.950 |
Why?
| | Proteomics | 14 | 2020 | 1111 | 0.930 |
Why?
| | Acute Kidney Injury | 3 | 2022 | 815 | 0.920 |
Why?
| | Biomarkers | 22 | 2023 | 4149 | 0.900 |
Why?
| | Tryptophan | 5 | 2024 | 183 | 0.880 |
Why?
| | Endocannabinoids | 4 | 2025 | 63 | 0.770 |
Why?
| | TRPP Cation Channels | 2 | 2024 | 85 | 0.770 |
Why?
| | Kynurenine | 5 | 2024 | 114 | 0.760 |
Why?
| | Endothelium, Vascular | 5 | 2021 | 927 | 0.760 |
Why?
| | Lovastatin | 2 | 2013 | 37 | 0.740 |
Why?
| | Pravastatin | 3 | 2023 | 41 | 0.710 |
Why?
| | Menopause | 3 | 2020 | 320 | 0.690 |
Why?
| | Arginine | 2 | 2024 | 271 | 0.680 |
Why?
| | Cannabinoids | 3 | 2024 | 161 | 0.680 |
Why?
| | Heart Defects, Congenital | 5 | 2025 | 842 | 0.670 |
Why?
| | Mass Spectrometry | 10 | 2021 | 739 | 0.650 |
Why?
| | Myocardium | 2 | 2017 | 1002 | 0.630 |
Why?
| | Adenosine | 3 | 2018 | 225 | 0.610 |
Why?
| | Glomerular Filtration Rate | 10 | 2023 | 746 | 0.610 |
Why?
| | Coronary Care Units | 1 | 2018 | 19 | 0.600 |
Why?
| | Signal Transduction | 11 | 2021 | 5079 | 0.600 |
Why?
| | Piperazines | 3 | 2009 | 350 | 0.600 |
Why?
| | Pyrimidines | 4 | 2014 | 470 | 0.570 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 445 | 0.560 |
Why?
| | Tacrolimus | 4 | 2017 | 199 | 0.560 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 35 | 0.550 |
Why?
| | Urine | 1 | 2017 | 59 | 0.550 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 32 | 0.540 |
Why?
| | Alkaline Phosphatase | 2 | 2018 | 148 | 0.520 |
Why?
| | Length of Stay | 4 | 2025 | 1215 | 0.510 |
Why?
| | Mycophenolic Acid | 3 | 2014 | 117 | 0.510 |
Why?
| | Animals | 42 | 2024 | 36940 | 0.490 |
Why?
| | Disease Models, Animal | 9 | 2024 | 4295 | 0.490 |
Why?
| | Adenosine Monophosphate | 1 | 2016 | 66 | 0.490 |
Why?
| | Plasma | 1 | 2017 | 212 | 0.490 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 257 | 0.480 |
Why?
| | Male | 51 | 2025 | 67762 | 0.470 |
Why?
| | Isoprostanes | 3 | 2012 | 15 | 0.460 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 320 | 0.460 |
Why?
| | Kidney Transplantation | 10 | 2018 | 708 | 0.450 |
Why?
| | Female | 49 | 2025 | 73304 | 0.440 |
Why?
| | Limit of Detection | 7 | 2024 | 85 | 0.440 |
Why?
| | Chromatography, Liquid | 8 | 2024 | 433 | 0.440 |
Why?
| | Humans | 72 | 2025 | 137585 | 0.440 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.430 |
Why?
| | Endothelium | 1 | 2014 | 123 | 0.430 |
Why?
| | Kidney Diseases | 4 | 2021 | 408 | 0.430 |
Why?
| | Disease Progression | 7 | 2023 | 2757 | 0.420 |
Why?
| | Cell Proliferation | 4 | 2024 | 2475 | 0.420 |
Why?
| | Oxylipins | 2 | 2025 | 40 | 0.420 |
Why?
| | Inflammation | 9 | 2025 | 2837 | 0.410 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2014 | 122 | 0.410 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.400 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 36 | 0.390 |
Why?
| | Proteome | 3 | 2016 | 472 | 0.390 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 76 | 0.390 |
Why?
| | Oncogene Proteins | 1 | 2012 | 59 | 0.390 |
Why?
| | Dinoprost | 5 | 2019 | 44 | 0.380 |
Why?
| | Mutation | 2 | 2022 | 3958 | 0.370 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 852 | 0.360 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 283 | 0.360 |
Why?
| | Plant Extracts | 2 | 2024 | 202 | 0.350 |
Why?
| | Rats | 16 | 2024 | 5647 | 0.350 |
Why?
| | Postoperative Complications | 3 | 2021 | 2654 | 0.350 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 167 | 0.350 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 263 | 0.350 |
Why?
| | Mitochondria | 1 | 2017 | 948 | 0.350 |
Why?
| | Nitric Oxide | 4 | 2024 | 915 | 0.340 |
Why?
| | Purines | 2 | 2022 | 176 | 0.340 |
Why?
| | Hypoxia | 6 | 2024 | 1112 | 0.330 |
Why?
| | Blotting, Western | 6 | 2012 | 1226 | 0.330 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 611 | 0.320 |
Why?
| | Mice, Inbred C57BL | 12 | 2023 | 5757 | 0.320 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 455 | 0.310 |
Why?
| | Prostaglandins | 3 | 2022 | 97 | 0.310 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 385 | 0.310 |
Why?
| | Ureteral Obstruction | 2 | 2021 | 64 | 0.300 |
Why?
| | Glycolysis | 4 | 2012 | 321 | 0.300 |
Why?
| | Theophylline | 2 | 2020 | 67 | 0.300 |
Why?
| | Mice | 19 | 2024 | 17787 | 0.300 |
Why?
| | Autophagy | 3 | 2024 | 284 | 0.300 |
Why?
| | Infant | 10 | 2025 | 9465 | 0.300 |
Why?
| | Antineoplastic Agents | 3 | 2009 | 2129 | 0.290 |
Why?
| | Arachidonate 12-Lipoxygenase | 2 | 2021 | 18 | 0.290 |
Why?
| | Arachidonate 15-Lipoxygenase | 2 | 2021 | 23 | 0.290 |
Why?
| | Mice, Knockout | 7 | 2023 | 3015 | 0.280 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3412 | 0.280 |
Why?
| | Amino Acids | 2 | 2025 | 497 | 0.280 |
Why?
| | Vascular Diseases | 2 | 2021 | 243 | 0.280 |
Why?
| | Case-Control Studies | 7 | 2024 | 3556 | 0.280 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2009 | 801 | 0.270 |
Why?
| | Blood Vessels | 2 | 2019 | 187 | 0.270 |
Why?
| | Reproducibility of Results | 11 | 2024 | 3284 | 0.260 |
Why?
| | Time Factors | 8 | 2022 | 6828 | 0.260 |
Why?
| | Infant, Newborn | 8 | 2025 | 6079 | 0.260 |
Why?
| | Rats, Wistar | 6 | 2018 | 455 | 0.250 |
Why?
| | Microsomes, Liver | 2 | 2019 | 86 | 0.250 |
Why?
| | Prospective Studies | 12 | 2025 | 7604 | 0.240 |
Why?
| | Deoxyglucose | 2 | 2024 | 53 | 0.240 |
Why?
| | Breast Neoplasms | 3 | 2017 | 2253 | 0.240 |
Why?
| | Swine | 3 | 2022 | 775 | 0.240 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 71 | 0.230 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.230 |
Why?
| | Mitragyna | 1 | 2024 | 5 | 0.230 |
Why?
| | Young Adult | 12 | 2023 | 13209 | 0.230 |
Why?
| | Alkaloids | 1 | 2024 | 30 | 0.230 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2015 | 69 | 0.230 |
Why?
| | Dronabinol | 2 | 2024 | 226 | 0.220 |
Why?
| | Glycerides | 1 | 2024 | 21 | 0.210 |
Why?
| | Treatment Outcome | 8 | 2021 | 10811 | 0.210 |
Why?
| | Arachidonic Acids | 1 | 2024 | 62 | 0.210 |
Why?
| | Citrulline | 1 | 2024 | 45 | 0.210 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 38 | 0.200 |
Why?
| | Graft Rejection | 4 | 2017 | 624 | 0.200 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 23 | 0.200 |
Why?
| | Adult | 17 | 2023 | 37929 | 0.200 |
Why?
| | Analgesia | 1 | 2024 | 94 | 0.200 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 3 | 2012 | 114 | 0.200 |
Why?
| | Tissue Distribution | 2 | 2014 | 332 | 0.200 |
Why?
| | Cytokines | 5 | 2025 | 2085 | 0.190 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 1 | 2022 | 25 | 0.190 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 565 | 0.190 |
Why?
| | Indoles | 1 | 2025 | 412 | 0.190 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.180 |
Why?
| | Nephritis | 1 | 2021 | 23 | 0.180 |
Why?
| | Aminophylline | 2 | 2020 | 10 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2021 | 513 | 0.180 |
Why?
| | Fetal Diseases | 1 | 2023 | 173 | 0.180 |
Why?
| | Curcumin | 1 | 2021 | 29 | 0.180 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 298 | 0.180 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 79 | 0.180 |
Why?
| | Child | 9 | 2023 | 21935 | 0.180 |
Why?
| | Calcium Channels, T-Type | 1 | 2022 | 96 | 0.170 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 46 | 0.170 |
Why?
| | Vascular Stiffness | 3 | 2021 | 494 | 0.170 |
Why?
| | Hypothalamus | 2 | 2018 | 153 | 0.170 |
Why?
| | Middle Aged | 16 | 2025 | 33479 | 0.170 |
Why?
| | Niacinamide | 1 | 2021 | 82 | 0.170 |
Why?
| | Databases, Genetic | 1 | 2022 | 237 | 0.170 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 122 | 0.170 |
Why?
| | Methionine | 1 | 2021 | 160 | 0.170 |
Why?
| | Benzamides | 3 | 2009 | 216 | 0.170 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2020 | 37 | 0.160 |
Why?
| | Cannabidiol | 1 | 2022 | 119 | 0.160 |
Why?
| | Complement Activation | 3 | 2018 | 415 | 0.160 |
Why?
| | Nephrectomy | 1 | 2021 | 169 | 0.160 |
Why?
| | Pain | 1 | 2025 | 756 | 0.160 |
Why?
| | Adolescent | 9 | 2021 | 21513 | 0.160 |
Why?
| | Vasodilation | 3 | 2018 | 499 | 0.160 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 80 | 0.160 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 17 | 0.160 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 69 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 88 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 37 | 0.150 |
Why?
| | Bone Marrow | 2 | 2017 | 286 | 0.150 |
Why?
| | Brain | 2 | 2013 | 2668 | 0.150 |
Why?
| | Spironolactone | 1 | 2019 | 36 | 0.150 |
Why?
| | Vitamin D | 2 | 2019 | 397 | 0.150 |
Why?
| | Blood Proteins | 1 | 2020 | 252 | 0.150 |
Why?
| | Glucose | 2 | 2017 | 1020 | 0.150 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 54 | 0.150 |
Why?
| | Homocysteine | 1 | 2019 | 156 | 0.150 |
Why?
| | Fontan Procedure | 1 | 2020 | 180 | 0.150 |
Why?
| | Complement Factor D | 1 | 2018 | 30 | 0.150 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 327 | 0.140 |
Why?
| | DNA Damage | 2 | 2019 | 420 | 0.140 |
Why?
| | Double-Blind Method | 5 | 2023 | 1993 | 0.140 |
Why?
| | 5'-Nucleotidase | 1 | 2018 | 41 | 0.140 |
Why?
| | Phenylpropionates | 1 | 2017 | 19 | 0.140 |
Why?
| | Group IV Phospholipases A2 | 1 | 2017 | 47 | 0.140 |
Why?
| | Sex Characteristics | 2 | 2013 | 762 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 204 | 0.140 |
Why?
| | Therapies, Investigational | 1 | 2017 | 17 | 0.140 |
Why?
| | Phenotype | 3 | 2022 | 3196 | 0.140 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2018 | 279 | 0.140 |
Why?
| | Complement Factor B | 1 | 2018 | 109 | 0.140 |
Why?
| | Metformin | 1 | 2021 | 331 | 0.140 |
Why?
| | Terbutaline | 1 | 2017 | 8 | 0.140 |
Why?
| | Cell Cycle | 2 | 2011 | 601 | 0.140 |
Why?
| | Endothelins | 1 | 2017 | 65 | 0.140 |
Why?
| | Pyridazines | 1 | 2017 | 56 | 0.140 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 83 | 0.140 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 119 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 697 | 0.130 |
Why?
| | Protein Kinases | 2 | 2017 | 319 | 0.130 |
Why?
| | Complement Factor H | 1 | 2018 | 80 | 0.130 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2018 | 198 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 152 | 0.130 |
Why?
| | Receptors, Calcitriol | 1 | 2017 | 55 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 185 | 0.130 |
Why?
| | Glutamic Acid | 1 | 2018 | 246 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2018 | 289 | 0.130 |
Why?
| | Brachial Artery | 4 | 2019 | 205 | 0.130 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.130 |
Why?
| | Calcineurin Inhibitors | 2 | 2014 | 72 | 0.130 |
Why?
| | Drug Synergism | 2 | 2014 | 382 | 0.130 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.130 |
Why?
| | Breast | 1 | 2017 | 151 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1167 | 0.120 |
Why?
| | Poly(ADP-ribose) Polymerases | 2 | 2013 | 98 | 0.120 |
Why?
| | Helminth Proteins | 1 | 2016 | 24 | 0.120 |
Why?
| | Extracellular Space | 1 | 2016 | 119 | 0.120 |
Why?
| | Solubility | 1 | 2016 | 245 | 0.120 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| | Premature Birth | 1 | 2019 | 333 | 0.120 |
Why?
| | Linoleic Acids | 1 | 2015 | 7 | 0.120 |
Why?
| | Transplant Recipients | 1 | 2017 | 184 | 0.120 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 40 | 0.120 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 43 | 0.120 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2031 | 0.120 |
Why?
| | Therapeutic Equivalency | 2 | 2017 | 32 | 0.120 |
Why?
| | Fishes | 1 | 2016 | 105 | 0.120 |
Why?
| | Reperfusion Injury | 1 | 2018 | 279 | 0.120 |
Why?
| | Enzyme Activation | 1 | 2017 | 810 | 0.120 |
Why?
| | Postoperative Period | 1 | 2016 | 342 | 0.120 |
Why?
| | Chi-Square Distribution | 1 | 2016 | 530 | 0.120 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2019 | 394 | 0.120 |
Why?
| | Diet, Sodium-Restricted | 1 | 2015 | 36 | 0.120 |
Why?
| | Aerosols | 1 | 2016 | 176 | 0.110 |
Why?
| | Biological Availability | 2 | 2017 | 148 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 139 | 0.110 |
Why?
| | Serine | 1 | 2015 | 141 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2016 | 652 | 0.110 |
Why?
| | Organ Size | 1 | 2015 | 477 | 0.110 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 433 | 0.110 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.110 |
Why?
| | Tidal Volume | 1 | 2014 | 86 | 0.110 |
Why?
| | Hospital Mortality | 1 | 2018 | 911 | 0.110 |
Why?
| | Macrophages, Alveolar | 2 | 2016 | 391 | 0.110 |
Why?
| | DNA Methylation | 1 | 2019 | 643 | 0.110 |
Why?
| | Respiration, Artificial | 2 | 2018 | 645 | 0.110 |
Why?
| | Aging | 2 | 2015 | 1864 | 0.110 |
Why?
| | Cannabis | 1 | 2021 | 494 | 0.110 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 23 | 0.110 |
Why?
| | Cattle | 1 | 2016 | 984 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2018 | 293 | 0.100 |
Why?
| | Everolimus | 2 | 2012 | 91 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 327 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2016 | 1316 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 107 | 0.100 |
Why?
| | Lung | 3 | 2022 | 4060 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | Pilot Projects | 4 | 2023 | 1710 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2071 | 0.100 |
Why?
| | Cell Death | 2 | 2013 | 374 | 0.100 |
Why?
| | Reactive Oxygen Species | 3 | 2012 | 622 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2426 | 0.100 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 54 | 0.100 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 11 | 0.100 |
Why?
| | Cytoprotection | 1 | 2012 | 56 | 0.100 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 74 | 0.100 |
Why?
| | Ion Transport | 1 | 2012 | 60 | 0.100 |
Why?
| | K562 Cells | 2 | 2009 | 89 | 0.100 |
Why?
| | Gluconeogenesis | 1 | 2012 | 79 | 0.100 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5472 | 0.100 |
Why?
| | Endothelial Cells | 2 | 2018 | 785 | 0.100 |
Why?
| | Glutamine | 1 | 2012 | 103 | 0.100 |
Why?
| | Nicorandil | 1 | 2012 | 11 | 0.100 |
Why?
| | Integrins | 1 | 2012 | 95 | 0.090 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 21 | 0.090 |
Why?
| | Fibronectins | 1 | 2012 | 133 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2828 | 0.090 |
Why?
| | Regression Analysis | 2 | 2012 | 1024 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 617 | 0.090 |
Why?
| | Androgens | 1 | 2013 | 187 | 0.090 |
Why?
| | Phosphates | 1 | 2012 | 182 | 0.090 |
Why?
| | Glucuronides | 1 | 2011 | 18 | 0.090 |
Why?
| | Lung Injury | 1 | 2014 | 219 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
| | Aged | 7 | 2025 | 23961 | 0.090 |
Why?
| | Cytoskeleton | 1 | 2012 | 191 | 0.090 |
Why?
| | Fatty Acids | 1 | 2014 | 443 | 0.090 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.090 |
Why?
| | Age Factors | 1 | 2018 | 3295 | 0.090 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2012 | 204 | 0.090 |
Why?
| | Models, Animal | 1 | 2013 | 384 | 0.090 |
Why?
| | Artifacts | 1 | 2011 | 129 | 0.090 |
Why?
| | Cell Survival | 2 | 2012 | 1120 | 0.080 |
Why?
| | Serotonin | 2 | 2024 | 323 | 0.080 |
Why?
| | Citric Acid Cycle | 1 | 2010 | 57 | 0.080 |
Why?
| | Drugs, Generic | 1 | 2010 | 22 | 0.080 |
Why?
| | Cross Reactions | 1 | 2010 | 133 | 0.080 |
Why?
| | Liver Transplantation | 1 | 2017 | 871 | 0.080 |
Why?
| | Estrogens | 1 | 2013 | 367 | 0.080 |
Why?
| | Flow Cytometry | 2 | 2014 | 1178 | 0.080 |
Why?
| | Proteinuria | 1 | 2010 | 97 | 0.080 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2007 | 180 | 0.080 |
Why?
| | Brain Ischemia | 1 | 2013 | 338 | 0.080 |
Why?
| | Drug Approval | 1 | 2010 | 88 | 0.080 |
Why?
| | Reference Standards | 1 | 2009 | 186 | 0.080 |
Why?
| | Heart Ventricles | 2 | 2024 | 788 | 0.080 |
Why?
| | Risk Assessment | 1 | 2018 | 3457 | 0.080 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 50 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2013 | 4193 | 0.080 |
Why?
| | Oncogenes | 1 | 2009 | 116 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1774 | 0.070 |
Why?
| | Lysosomes | 2 | 2021 | 141 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1946 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2012 | 294 | 0.070 |
Why?
| | Cross-Over Studies | 3 | 2017 | 564 | 0.070 |
Why?
| | Antioxidants | 1 | 2012 | 584 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
| | Astrocytes | 1 | 2010 | 210 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1759 | 0.070 |
Why?
| | Phospholipids | 1 | 2009 | 223 | 0.070 |
Why?
| | Lactic Acid | 1 | 2009 | 305 | 0.070 |
Why?
| | F2-Isoprostanes | 2 | 2018 | 21 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 518 | 0.070 |
Why?
| | Intestinal Mucosa | 1 | 2012 | 623 | 0.070 |
Why?
| | Apoptosis | 3 | 2012 | 2553 | 0.070 |
Why?
| | Fibrosis | 2 | 2021 | 552 | 0.070 |
Why?
| | Food Hypersensitivity | 1 | 2010 | 183 | 0.070 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2021 | 171 | 0.060 |
Why?
| | Allergens | 1 | 2010 | 409 | 0.060 |
Why?
| | Drug Monitoring | 1 | 2008 | 218 | 0.060 |
Why?
| | Nucleotides | 1 | 2007 | 125 | 0.060 |
Why?
| | Hydroxylation | 2 | 2019 | 39 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1096 | 0.060 |
Why?
| | Estradiol | 2 | 2020 | 521 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 406 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2057 | 0.060 |
Why?
| | Hypertension | 1 | 2015 | 1295 | 0.060 |
Why?
| | Pulse Wave Analysis | 2 | 2018 | 272 | 0.060 |
Why?
| | Palliative Care | 2 | 2024 | 758 | 0.060 |
Why?
| | Indoleacetic Acids | 1 | 2025 | 10 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2024 | 412 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1692 | 0.060 |
Why?
| | Kynurenic Acid | 1 | 2024 | 20 | 0.060 |
Why?
| | HIV Infections | 1 | 2019 | 2836 | 0.060 |
Why?
| | Isomerism | 1 | 2024 | 56 | 0.060 |
Why?
| | Risk Factors | 1 | 2018 | 10388 | 0.060 |
Why?
| | Blood Pressure | 3 | 2019 | 1786 | 0.050 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1120 | 0.050 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 33 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 94 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 2992 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 147 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 2295 | 0.050 |
Why?
| | Morbidity | 1 | 2024 | 324 | 0.050 |
Why?
| | bcl-2-Associated X Protein | 2 | 2013 | 56 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 34 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 56 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 1066 | 0.050 |
Why?
| | Urinalysis | 2 | 2015 | 77 | 0.050 |
Why?
| | Drug Interactions | 2 | 2017 | 410 | 0.050 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2021 | 37 | 0.050 |
Why?
| | Steroids | 1 | 2022 | 167 | 0.050 |
Why?
| | Cell Line | 2 | 2021 | 2847 | 0.050 |
Why?
| | Pregnancy | 3 | 2019 | 6763 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 142 | 0.040 |
Why?
| | Rats, Inbred Lew | 2 | 2012 | 114 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 84 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 78 | 0.040 |
Why?
| | Drug Stability | 2 | 2011 | 167 | 0.040 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 79 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2021 | 62 | 0.040 |
Why?
| | Pharmacokinetics | 1 | 2020 | 29 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 172 | 0.040 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2020 | 26 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2022 | 200 | 0.040 |
Why?
| | Cohort Studies | 2 | 2023 | 5742 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 125 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 129 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 148 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 311 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2015 | 1272 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 15 | 0.040 |
Why?
| | Molecular Structure | 2 | 2014 | 489 | 0.040 |
Why?
| | Pulmonary Veins | 1 | 2020 | 99 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 81 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 62 | 0.040 |
Why?
| | Administration, Oral | 2 | 2012 | 816 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2019 | 88 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2019 | 155 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1278 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Reference Values | 2 | 2013 | 816 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 180 | 0.040 |
Why?
| | Creatinine | 1 | 2020 | 499 | 0.040 |
Why?
| | Complement C5a | 1 | 2018 | 71 | 0.040 |
Why?
| | Complement Membrane Attack Complex | 1 | 2018 | 39 | 0.040 |
Why?
| | Rewarming | 1 | 2018 | 20 | 0.040 |
Why?
| | GPI-Linked Proteins | 1 | 2018 | 73 | 0.030 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2167 | 0.030 |
Why?
| | Position-Specific Scoring Matrices | 1 | 2017 | 2 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2021 | 956 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 186 | 0.030 |
Why?
| | Femoral Artery | 1 | 2018 | 179 | 0.030 |
Why?
| | Birth Weight | 1 | 2020 | 516 | 0.030 |
Why?
| | Half-Life | 1 | 2017 | 164 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 530 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 282 | 0.030 |
Why?
| | Malates | 1 | 2016 | 7 | 0.030 |
Why?
| | Carotid Arteries | 1 | 2018 | 206 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 366 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1060 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 138 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 225 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 73 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 42 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 350 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 372 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 2057 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 574 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 479 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 656 | 0.030 |
Why?
| | Aldehydes | 1 | 2016 | 145 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 409 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 916 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 54 | 0.030 |
Why?
| | Safety | 1 | 2017 | 338 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 327 | 0.030 |
Why?
| | Larva | 1 | 2016 | 226 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 23 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 18 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2017 | 844 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 257 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 305 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 394 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 84 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 65 | 0.030 |
Why?
| | Kinetics | 1 | 2018 | 1670 | 0.030 |
Why?
| | Prognosis | 2 | 2013 | 4030 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 688 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 54 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 92 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1509 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 123 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 12 | 0.030 |
Why?
| | Macrophages | 1 | 2021 | 1547 | 0.030 |
Why?
| | Binding Sites | 1 | 2017 | 1303 | 0.030 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2013 | 122 | 0.030 |
Why?
| | Dihydrotestosterone | 1 | 2013 | 44 | 0.030 |
Why?
| | Orchiectomy | 1 | 2013 | 71 | 0.030 |
Why?
| | Child, Preschool | 2 | 2020 | 11074 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2015 | 474 | 0.030 |
Why?
| | Altitude | 1 | 2017 | 488 | 0.020 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2013 | 50 | 0.020 |
Why?
| | Cell Count | 1 | 2013 | 324 | 0.020 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2013 | 40 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2013 | 171 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 684 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 209 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 73 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 346 | 0.020 |
Why?
| | Streptozocin | 1 | 2012 | 21 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2013 | 150 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 195 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1113 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 177 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1793 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 558 | 0.020 |
Why?
| | Neuroprotective Agents | 1 | 2013 | 131 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 195 | 0.020 |
Why?
| | Caspase 3 | 1 | 2012 | 246 | 0.020 |
Why?
| | Transplantation | 1 | 2011 | 34 | 0.020 |
Why?
| | Podocytes | 1 | 2012 | 69 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 579 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 653 | 0.020 |
Why?
| | Drug-Eluting Stents | 1 | 2011 | 81 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1396 | 0.020 |
Why?
| | Methylation | 1 | 2011 | 230 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2224 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 275 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2012 | 195 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 605 | 0.020 |
Why?
| | Daucus carota | 1 | 2010 | 1 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 376 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2010 | 19 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 622 | 0.020 |
Why?
| | Buffers | 1 | 2010 | 56 | 0.020 |
Why?
| | Graft Survival | 1 | 2012 | 535 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 886 | 0.020 |
Why?
| | Hot Temperature | 1 | 2012 | 391 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 158 | 0.020 |
Why?
| | Antigens, Plant | 1 | 2010 | 54 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1783 | 0.020 |
Why?
| | Body Mass Index | 1 | 2018 | 2389 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1325 | 0.020 |
Why?
| | Ribose | 1 | 2009 | 23 | 0.020 |
Why?
| | Plant Proteins | 1 | 2010 | 113 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2010 | 385 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2020 | 15657 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 363 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 10 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 840 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 82 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 132 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 208 | 0.020 |
Why?
| | Vegetables | 1 | 2010 | 157 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2009 | 144 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2486 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 860 | 0.020 |
Why?
| | Liver | 1 | 2016 | 1943 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2010 | 340 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 445 | 0.020 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 976 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2139 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1916 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2844 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2900 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4565 | 0.010 |
Why?
| | Neurons | 1 | 2013 | 1590 | 0.010 |
Why?
| | Ischemia | 1 | 2007 | 409 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 2607 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 2008 | 570 | 0.010 |
Why?
| | United States | 1 | 2010 | 14841 | 0.010 |
Why?
|
|
Klawitter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|